Provided by Tiger Trade Technology Pte. Ltd.

Pasithea Therapeutics Corp.

0.5400
-0.0297-5.21%
Post-market: 0.54000.00000.00%16:10 EDT
Volume:246.80K
Turnover:134.60K
Market Cap:18.04M
PE:-0.36
High:0.5759
Open:0.5701
Low:0.5200
Close:0.5697
52wk High:2.06
52wk Low:0.2810
Shares:33.41M
Float Shares:10.20M
Volume Ratio:1.17
T/O Rate:2.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4820
EPS(LYR):-2.9100
ROE:-65.49%
ROA:-36.00%
PB:0.36
PE(LYR):-0.19

Loading ...

Pasithea Therapeutics Corp - Initiates Pilot Food Effect Study for Pas-4 Pharmacokinetics

THOMSON REUTERS
·
Jun 30

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-term Safety and Tolerability, and Durable Clinical Activity in Mek/braf-pretreated Patients, Plus Protocol Expansion

THOMSON REUTERS
·
Jun 30

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

GlobeNewswire
·
Jun 30

Major Investor Quietly Boosts Stake in Pasithea Therapeutics

TIPRANKS
·
Jun 23

Coastlands Capital LP buys 100,000 Pasithea Therapeutics shares for $53,000

Reuters
·
Jun 22

Analysts Are Bullish on Top Healthcare Stocks: Pasithea Therapeutics Corp (KTTA), Adaptive Biotechnologies (ADPT)

TIPRANKS
·
Jun 16

Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 16

Pasithea Therapeutics Amends PAS-004 Trial to Add Higher Dose Levels, Extend Treatment

MT Newswires Live
·
Jun 16

Pasithea Therapeutics expands PAS-004 Phase 1/1b NF1 trial with higher dose cohorts

Reuters
·
Jun 16

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B Nf1 Clinical Trial

THOMSON REUTERS
·
Jun 16

Pasithea Therapeutics - Amendments Add 24Mg and 32Mg Dose Levels and Backfilling of Cohorts in Phase 1/1B Trial

THOMSON REUTERS
·
Jun 16

Pasithea Therapeutics - on Track to Release Interim Nf1 Data Update in Q4 2026

THOMSON REUTERS
·
Jun 16

Pasithea Therapeutics - Amendments Extend Treatment to 18 Months and Add Mri Scans and Cn Measurements

THOMSON REUTERS
·
Jun 16

Pasithea Therapeutics to exhibit at Children’s Tumor Foundation NF Conference

Reuters
·
Jun 15

Pasithea says FDA grants orphan drug designation for PAS-004 in ALS

Reuters
·
Jun 02

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of Pas-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

THOMSON REUTERS
·
Jun 02

Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis

TIPRANKS
·
May 30

Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?

Simply Wall St.
·
May 24

Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained

TIPRANKS
·
May 21

Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) Estimate

Benzinga Earnings
·
May 16